NEOGEN CORP — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Neogen reported Q1 FY2027 revenue of $222.8M (6.5% growth; 8.1% core growth), with Food Safety up 7.4% to $163.2M and Animal Safety up 4.2% to $59.6M. Net loss was $11.9M (GAAP) but Adjusted Net Income was $17.5M ($0.08 EPS). The company raised full-year FY2027 guidance to $885–$890M revenue and $181–$183M Adjusted EBITDA (from prior $880–$885M and $180–$182M). Key milestones include first Petrifilm SKU validation completed August 2026, with manufacturing transition to begin November 2026; Hinalea Imaging strategic partnership and equity investment announced; Genomics business sale to Zoetis expected to close by end-December 2026.
Why this rating
Modest revenue growth (6.5% reported, 8.1% core) with guidance raise and margin expansion signal stabilization post-3M integration. Petrifilm manufacturing ramp is operationally important but not transformational. 4.3% revenue range lift ($5M midpoint) is ~0.5% of market cap; material for execution but not business-altering.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.